1. , , . Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 2006;25:156–61.
2. , , . Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 2007;52:842–7.
3. , , , et al. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol 2005;174:2032–6.
4. , , , et al. The effects of tolterodine on bladder-filling sensations and perception thresholds to intravesical electrical stimulation: method and initial results. BJU Int 2007;100:574–8.
5. , , , et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci USA 2000;97:9579–84.
6. , , , . Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 2004;309:1148–53.
7. , , , et al. Ca2+ sensitization in contraction of human bladder smooth muscle. J Urol 2004;172:748–52.
8. , , , et al. The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J Pharmacol Exp Ther 2005;313:368–78.
9. , , . The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol 2004;286:R874–80.
10. , . Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol 2007;4:46–54.
11. , , , et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 2006;176:367–73.
12. , , , et al. Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in urothelium and its clinical significance. J Pharmacol Sci 2008;106:193–8.
13. , , , et al. Non-neuronal cholinergic system in human bladder urothelium. Urology 2006;67:425–30.
14. , , , et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009;19:380–94.
15. , , , . Dementia and lower urinary dysfunction: with a reference to anticholinergic use in elderly population. Int J Urol 2008;15:778–88.
16. , , , . Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 2006;98:503–7.
17. , , , . The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48:5–26.
18. , , , . Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003;326:841–4.
19. , , , et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543–62.
20. , , , et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54:740–63.
21. , , , et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998;280:1995–2000.
22. , , , et al. Neurologic urinary and faecal incontinence. In: , , , , eds. Incontinence. Paris: Health Publication Ltd; 2009:793–960.
23. , , , . Bladder dysfunction in dementia patients showing urinary incontinence: evaluation with cystometry and treatment with propiverine hydrochloride. Nippon Ronen Igakkai Zasshi 1999;36:489–94.
24. , , , . Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev 2009:CD004193.
25. , , , et al. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008;53:1021–8.
26. , , , , . Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006;25:441–5.
27. . Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46–53.
28. , , . Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003;4:436–40.
29. , , . Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41:636–44.
30. . Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003;42:1243–85.
31. , . Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008;62:1792–800.
32. , , , et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005;53:2195–201.
33. , . Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 2005;27:127–38.
34. , , , et al. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 2007;68:1809–14.
35. , , . Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med Sci Monit 2000;6:314–18.
36. , , , et al. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2003;74:70–6.
37. , , , et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148:565–78.
38. , . Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res 2004;145:59–66.
39. , , , et al. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry 2003;8:673–9.
40. , , , et al. M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci 2004;24:10117–27.
41. , , , et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 2001;410:207–12.
42. , , , et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003;6:51–8.
43. . M1 muscarinic agonists target major hallmarks of Alzheimer's disease – the pivotal role of brain M1 receptors. Neurodegener Dis 2008;5:237–40.
44. , , , et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465–73.
45. , , , et al. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 2007;30:54–8.
46. , , , et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006;50:317–26.
47. , , . The effects of anticholinergic drugs on attention span and short-term memory skills in children. Neurourol Urodyn 2008;27:315–18.
48. , , , et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998;46:8–13.
49. , , , , . Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry 2010;81:160–5.
50. , , , , . Cognitive impairments and depression in Parkinson's disease: a follow up study. J Neurol Neurosurg Psychiatry 1990;53:597–602.
51. , , , et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009;56:81–8.
52. , , , . Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis. Br J Urol 1994;74:733–5.
53. , , . The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatry 1983;46:854–5.
54. , , . Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996;53:1270–5.
55. , , , , . The use of desmopressin in the management of nocturnal enuresis in patients with spinal cord injury. Eura Medicophys 2007;43:333–8.
56. , , . Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn 2006;25:105–9.
57. , , . The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976;48:255–63.
58. . The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 2001;88(Suppl 2):27–34.
59. . A study of the adrenotropic receptors. Am J Physiol 1948;153:586–600.
60. . Presynaptic regulation of catecholamine release. Biochem Pharmacol 1974;23:1793–800.
61. . Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 2002;19:390–6.
62. , , . Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 1999;161:635–40.
63. , , , et al. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol 1993;150:546–51.
64. , , , et al. Alpha1-adrenergic receptor subtypes in human detrusor. J Urol 1998;160:937–43.
65. , , , et al. Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 2002;167:1513–21.
66. , . Molecular pharmacology of human alpha1-adrenergic receptors: unique features of the alpha 1a-subtype. Eur Urol 1999;36(Suppl 1):7–10.
67. , , , et al. The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Br J Pharmacol 1997;120:231–8.
68. , , , et al. A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. J Urol 2006;176:1236–41.
69. , , , et al. The influence of alpha1-adrenoreceptors on neuropeptide release from primary sensory neurons of the lower urinary tract. Eur Urol 2007;52:901–8.
70. , , , et al. Improvement in bladder storage function by tamsulosin depends on suppression of C-fiber urethral afferent activity in rats. J Urol 2007;177:771–5.
71. , , , . A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int 2007;100:840–5.
72. . Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993;45:253–308.
73. , . Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147(Suppl 2):S88–119.
74. , , , , . Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol 2008;377:473–81.
75. , , , et al. Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzo dioxole-2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats. J Pharmacol Exp Ther 2008;326:178–85.
76. , , , , . Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 2008;377:449–62.
77. , , , et al. Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol 2002;168:1247–52.
78. . Emerging drugs for treatment of overactive bladder and detrusor overactivity. Expert Opin Emerg Drugs 2008;13:431–46.
79. , , , et al. Clinical proof of concept study (blossom) shows novel β3 adrenoceptor agonist ym178 is effective and well tolerated in the treatment of symptoms of overactive bladder. European Urol Supplements 2008;7:239.
80. , . Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004;84:935–86.
81. , , , . Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn 2007;26:928–33.
82. , , , et al. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 2001;19:344–50.
83. , , , et al. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction. BJU Int 2008;101:615–20.
84. . Phosphodiesterase-linked inhibition of nonmicturition activity in the isolated bladder. BJU Int 2004;93:1325–32.
85. . Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005;5:238–44.
86. , , , , . A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236–44.
87. , , , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401–7.
88. , , , et al. Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol 2009;181:1939–48.
89. , , , et al. Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats. Urology 2007;70:202–8.
90. , , , et al. Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol 2009;181:1932–8.
91. , , , et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004;10:425–33.
92. , , , et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006;17:636–41.
93. , , , . Randomised controlled trial of sativex to treat detrusor over activity in multiple sclerosis. JNNP 2010;submitted.
94. , , , et al. The molecular basis of urgency: regional difference of vanilloid receptor expression in the human urinary bladder. Neurourol Urodyn 2007;26:433–8.
95. , , , et al. GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol 2009;181:379–86.
96. , , , et al. The TRPV4 cation channel mediates stretch-evoked Ca2+ influx and ATP release in primary urothelial cell cultures. J Biol Chem 2009;284:21257–64.
97. , , , et al. Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest 2007;117:3453–62.
98. , , , et al. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 1990;30(Suppl):S71–7.
99. , , . The role of sensory nerve endings in neurogenic inflammation induced in human skin and in the eye and paw of the rat. Br J Pharmacol Chemother 1968;33:32–41.
100. , , , , . Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992;339:1239.
101. . Physiology, phylogeny, and functions of the TRP superfamily of cation channels. Sci STKE 2001;RE1.
102. , , , et al. Ligand-induced dynamic membrane changes and cell deletion conferred by vanilloid receptor 1. J Biol Chem 2001;276:11021–30.
103. , , . Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1. J Biol Chem 2001;276:31163–70.
104. , , , et al. Resiniferatoxin-induced loss of plasma membrane in vanilloid receptor expressing cells. Neurotoxicology 2003;24:895–908.
105. , , , , . The effect of intravesical capsaicin on the suburothelial innervation in patients with detrusor hyper-reflexia. BJU Int 2000;85:238–45.
106. , , , et al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 2004;93:770–6.
107. , . TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol 2006;373:287–99.
108. , , . Electromotive drug administration of lidocaine to anesthetize the bladder before intravesical capsaicin. J Urol 1998;159:1857–61.
109. , , , et al. Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. Urology 2005;65:400–5.
110. , , , et al. Endothelial nitric oxide synthase (eNOS) expression in neurogenic urinary bladders treated with intravesical resiniferatoxin (RTX). BJU Int 2004;93:336–40.
111. , , , et al. Intravesical instillation of capsaicin in urology: a review of the literature. Eur Urol 1999;36:267–77.
112. , . Intravesical therapy options for neurogenic detrusor overactivity. Spinal Cord 2004;42:267–72.
113. , , , . Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. J Spinal Cord Med 2008;31:157–65.
114. , , . Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia. Eur Urol 2000;38:444–52.
115. . Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions. J Urol 2003;170:835–9.
116. , , , et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 2002;167:1710–14.
117. , , , et al. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med 2003;26:358–63.
118. , , , , . Treating the human bladder with capsaicin: is it safe? Eur Urol 1998;33:28–31.
119. , , , et al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004;172:240–3.
120. , , , et al. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow-up. J Urol 1997;158:2087–92.
121. , , , et al. Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol 2004;171:251–5.
122. , , , , , . Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. J Urol 2000;164:676–9.
123. , , , , . Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases. Scand J Urol Nephrol 1998;32:331–4.
124. , , , . A light- and electron-microscopic histopathological study of human bladder mucosa after intravesical resiniferatoxin application. BJU Int 2001;88:355–60.
125. , , , . Nociceptin and the micturition reflex. Peptides 2000;21:1007–21.
126. , , , et al. Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study. J Urol 2001;166:2237–40.
127. , , , et al. Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study. Urology 2003;61:946–50.
128. , , . Long-term exposure to local but not inhalation anesthetics affects neurite regeneration and synapse formation between identified lymnaea neurons. Anesthesiology 2005;102:353–63.
129. , , . Intravesical lignocaine and detrusor instability. Br J Urol 1979;51:500–3.
130. . Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 2005;65:45–8.
131. , , , et al. Daily intravesical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study. J Urol 2006;176:2098–102.
132. , , , . The effects of intravesical lidocaine on bladder dynamics of children with myelomeningocele. J Urol 2001;165:2380–2.
133. , , , et al. Neurologic urinary and fecal incontinence. In: , , , , eds. Incontinence. Paris: Health Publications Ltd; 2004:1059–162.
134. . Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003;43(Suppl 1):S16–24.
135. , , , , . Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96:3200–5.
136. . Clinical comparisons of botulinum neurotoxin formulations. Neurologist 2008;14:289–98.
137. , . Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int 2007;99:247–62.
138. , , , , . Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988;139:919–22.
139. , , , et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003;169:1896–900.
140. , , . Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49:644–50.
141. , , , et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;174:977–82.
142. , , , et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006;175:2341–4.
143. , , , et al. Cholinergic signalling pathways in the superficial layers of the human bladder: Comparing health, disease and the effect of botulinum toxin type A. J Urol 2009;181:676–7.
144. , , , et al. Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment. Eur Urol 2009;55:1440–9.
145. , , , , . Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004;45:987–93.
146. , , . Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245–58.
147. , , , . Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125–33.
148. , , , , . Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 2004;172:1529–32.
149. , , , , , . Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692–7.
150. , , , , . A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003;92:325–6.
151. , , , et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European Consensus Report. Eur Urol 2009;51:100–19.
152. , , , et al. Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 2007;177:1011–14.
153. , , , et al. Une antibioprophylaxie est-elle necessaire lors de la realisation d'injections intradetrusoriennes de toxine botulique A dans le traitement d'une hyperactivite detrusorienne neurogene? Prog Urol 2009;19:667.
154. , , , et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007;62:452–7.
155. , , . Aminoglycosides and 3,4-diaminopyridine on neuromuscular block caused by botulinum type A toxin. Muscle Nerve 1987;10:464–70.
156. , . Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002;40:599–600.
157. , , , et al. Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur Urol 2008;54:181–7.
158. , , , et al. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 2004;63:1071–5.
159. , , , et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004;45:510–15.
160. , , , et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174:196–200.
161. , , , et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 2007;41:335–40.
162. , , , et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005;174:984–8.
163. , , , et al. Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre. Eur Urol 2008;53:1013–20.
164. , , , et al. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 2005;66:865–70.
165. , , , . Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 2009;55:705–11.
166. . Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 2006;68:993–7.
167. , , , et al. What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 2006;97:1030–4.
168. . Botulinum-A toxin in the treatment of detrusor hyperreflexia. 31st Annual Meeting of the International Continence Society, Seoul, Korea, 2001: Abstract 2001.
169. , , , , . Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005;24:231–6.
170. . Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004;63:868–72.
171. , , , et al. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 2006;25:110–15.
172. , , . Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47:653–9.
173. , , , et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006;49:519–27.
174. , , , et al. Sustained and significant quality of life improvement after intra-detrusor botulinum toxin type A injections for neurogenic detrusor overactivity secondary to multiple sclerosis. Br J Urol 2009;103:37.
175. , , , . Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006;68:17–28.
176. , , , et al. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 2007;52:850–8.
177. , , , et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2008;53:613–18.
178. , , , et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX®) therapy in Germany. World J Urol; DOI 10.1007/s00345-009-0466-1 (not yet published in journal).
179. , , . Baclofen in the treatment of detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1980;124:82–4.
180. , , , et al. Side effects of chronic intrathecal baclofen on erection and ejaculation in patients with spinal cord lesions. Arch Phys Med Rehabil 1998;79:494–6.
181. , , . Use of dantrolene sodium in external sphincter spasm. Urology 1976;8:133–7.
182. , , , et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003;170:1242–51.
183. , , , . Oral nitric oxide donors: a new pharmacological approach to detrusor-sphincter dyssynergia in spinal cord injured patients? Eur Urol 2004;45:516–20.